Biosergen

Biosergen EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biosergen (BIOSGN.ST) as of Oct 19, 2026 is -41.39 M SEK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -20.69 M SEK — a change of 100.04% (lower).

EBITDA

-41.39 MSEK

YoY

100.04%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biosergen is 2025 -41.39 M SEK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biosergen was 2024 -20.69 M SEK. It decreases by 100.04% lower compared to the previous year.

The Biosergen EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-5.16 M SEK
Jan 1, 2020
-6.23 M SEK
Jan 1, 2021
-34.08 M SEK
Jan 1, 2022
-34.13 M SEK
Jan 1, 2023
-27.27 M SEK
Jan 1, 2024
-20.69 M SEK
Jan 1, 2025
-41.39 M SEK
The Biosergen EBITDA history
YEAREBITDAYoY
-41.39 MSEK+100.04%
-20.69 MSEK-24.11%
-27.27 MSEK-20.11%
-34.13 MSEK+0.15%
-34.08 MSEK+447.35%
-6.23 MSEK+20.75%
-5.16 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biosergen Stock analysis

What does Biosergen do? Biosergen AB is a biopharmaceutical company headquartered in Solna, Sweden. The company went public on June 24, 2021, with its ticker symbol BIOSGN.ST and ISIN SE0026821852. Biosergen AB conducts biopharmaceutical research and development through its subsidiary Biosergen AS, utilizing laboratory facilities in Trondheim, Norway, and other global locations. The company is focused on developing BSG005, an antifungal drug that has shown safety and potency benefits compared to existing treatments. BSG005 is designed to address invasive fungal infections affecting immune-compromised patients, including those with AIDS, cancer, or who have undergone transplants. At equivalent doses, BSG005 has demonstrated a three- to fourfold higher potency against targeted fungal strains than current standard treatments, while avoiding the kidney toxicity associated with other drugs in its class. Biosergen AB operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is biosergen.net, providing further information about its research and development activities. The firm's primary focus remains on advancing BSG005 through clinical development, targeting a significant unmet medical need in the treatment of fungal infections among vulnerable patient populations. Biosergen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biosergen stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biosergen is -41.39 M SEK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Biosergen changed from -20.69 M SEK to -41.39 M SEK, representing a 100.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Biosergen since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Biosergen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biosergen

All Key Metrics — Biosergen